Table 4.
Univariable Analysis | Multivariable Analysis | |||||||
---|---|---|---|---|---|---|---|---|
B | OR | 95%CI | P | B | OR | 95%CI | P | |
Male | −0.3 | 0.741 | 0.618–0.888 | 0.001 | −0.403 | 0.668 | 0.541–0.826 | <0.001 |
Age | 0.027 | 1.028 | 1.019–1.037 | <0.001 | 0.025 | 1.025 | 1.014–1.036 | <0.001 |
Smoking | −0.224 | 0.799 | 0.629–1.016 | 0.067 | −0.035 | 0.965 | 0.72–1.293 | 0.812 |
Drinking | −0.316 | 0.729 | 0.563–0.944 | 0.017 | −0.009 | 0.991 | 0.734–1.339 | 0.954 |
Hypertension | 0.207 | 1.229 | 1.016–1.487 | 0.033 | 0.064 | 1.066 | 0.861–1.318 | 0.559 |
Diabetes | 0.413 | 1.511 | 1.251–1.825 | <0.001 | 0.283 | 1.326 | 1.078–1.632 | 0.008 |
eGFR | −0.008 | 0.992 | 0.989–0.996 | <0.001 | 0.004 | 1.004 | 0.999–1.009 | 0.097 |
Uric acid | 0 | 1 | 0.999–1.001 | 0.901 | ||||
LDL-C | 0.003 | 1.003 | 0.913–1.102 | 0.945 | ||||
CRP | 0.012 | 1.013 | 1.009–1.016 | <0.001 | 0.01 | 1.011 | 1.007–1.014 | <0.001 |
LVEF | −0.025 | 0.975 | 0.969–0.981 | <0.001 | −0.026 | 0.974 | 0.967–0.981 | <0.001 |
Excess volumes of CM | 0.571 | 1.77 | 1.241–2.526 | 0.002 | 0.615 | 1.85 | 1.205–2.84 | 0.005 |
Iso-osmolar CM | 0.001 | 1.001 | 0.831–1.204 | 0.996 | ||||
Contrast Volume | 0.001 | 1.001 | 1–1.002 | 0.119 | ||||
Types of statins, Atorvastatin | 0.083 | 1.087 | 0.929–1.271 | 0.297 | 0.051 | 1.052 | 0.887–1.249 | 0.558 |
Prior myocardial infarction history | 0.164 | 1.178 | 0.64–2.168 | 0.598 | ||||
Prior PCI history | 0.075 | 1.077 | 0.754–1.54 | 0.682 | ||||
CABG history | −0.946 | 0.388 | 0.051–2.973 | 0.362 | ||||
Cardiac surgery history (except CABG) | 0.814 | 2.257 | 0.693–7.353 | 0.177 | ||||
Angiography combined with PCI | 0.202 | 1.224 | 1.027–1.459 | 0.024 | ||||
Multi vessel PCI | 0.035 | 1.035 | 0.813–1.318 | 0.779 | ||||
Total length of stents | −0.005 | 0.995 | 0.989–1.001 | 0.127 |
Abbreviations: PC-AKI post-contrast acute kidney injury, eGFR estimated glomerular filtration rate, LDL-C low-density lipoprotein cholesterol, CRP C-reactive protein, LVEF left ventricular ejection fractions, CM contrast medium, ACEI angiotensin converting enzyme inhibitors, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting